Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NF-κB

Molecular Medicine Reports

Volumn 9, Issue 1, 2014, Pages 249-254

  Yu, Meiling ^a   Tong, Xuhui ^a   Qi, Benquan ^a   Qu, Hongdang ^a   Dong, Shuying ^a   Yu, Binbin ^a   Zhang, Naiju ^a   Tang, Nan ^b   Wang, Lingzhi ^c   Zhang, Cuiling ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Berberine; Irinotecan; Nuclear factor B

Indexed keywords

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BERBERINE; CAMPTOTHECIN; COLONIC NEOPLASMS; DOWN-REGULATION; DOXORUBICIN; FLUOROURACIL; HCT116 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NF-KAPPA B; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA;

EID: 84893868630     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1762     Document Type: Article

References (24)

1. Sarkar FH and Li Y: Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 35: 597-607, 2009.
2. Li F and Sethi G: Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805: 167-180, 2010.
3. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274: 787-789, 1996.
4. Cusack JC Jr, Liu R and Baldwin AS Jr: Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res 60: 2323-2330, 2000.
5. Baldwin AS Jr: Series introduction: the transcription factor NF-kappaB and human disease. J Clin Investig 107: 3-6, 2001.
6. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
7. Xu Y and Villalona-Calero MA: Irinotecan: mechanism of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13: 1841-1851, 2002.
8. Wasserman E, Sutherland W and Cvitkovic E: Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer. Clin Colorectal Cancer 1: 149-153, 2001.
9. Stahel RA and Zangemeister-Wittke U: Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer 41 (Suppl 1): S81-S88, 2003.
10. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J and Callery MP: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82: 110-122, 2001.
11. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J and Baldwin AS Jr: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61: 3535-3540, 2001.
12. Guo J, Verma UN, Gaynor RB, Frenkel EP and Becerra CR: Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 10: 3333-3341, 2004.
13. Lagdec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, Imbert V, Mari M, Hofman P, Czerucka D, Rousseau D, et al.: Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer 98: 335-344, 2008.
14. Liu S, Fang Y, Shen H, Xu W and Li H: Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis. Acta Biochim Biophys Sin (Shanghai) 45: 756-762, 2013.
15. Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM and Aggarwal BB: Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res 68: 5370-5379, 2008.
16. Papazisis KT, Geromichalos GD, Dimitriadis KA and Kortsaris AH: Optimization of the sulforhodamine B colorimetric assay. J Immumol Methods 208: 151-158, 1997.
17. Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al Abdulmohsen S, Platanias LC, Al-Kuraya KS and Uddin S: Cross-Talk between NF-κB and the PI3-Kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 7: e39945, 2012.
18. Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS and Uddin S: Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 7: 3318-3329, 2008.
19. Wang Q, Zhang J, Liu L, Sharma S and Dong Q: Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One 7: e51764, 2012.
20. Zou Z, Xie L, Wei J, Yu L, Qian X, Chen J, Wang T and Liu B: Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines. BMC Complement Altern Med 12: 58, 2012.
21. Kawano Y, Nagata M, Kohno T, Ichimiya A, Iwakiri T, Okumura M and Arimori K: Caffeine increases the antitumor effect of Cisplatin in human hepatocellular carcinoma cells. Biol Pharm Bull 35: 400-407, 2012.
22. Pacifico F and Leonardi A: Role of NF-kappaB in thyroid cancer. Mol Cell Endocrinol 321: 29-35, 2010.
23. Baud V and Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40, 2009.
24. Kuoharczak J, Simmons MJ, Fan Y and Gélinas C: To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22: 8961-8982, 2003.